QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.104.072363v1 312/1/192    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rytting, E. Articles by Audus, K. L. Search for Related Content PubMed PubMed Citation Articles by Rytting, E. Articles by Audus, K. L.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Novel Organic Cation Transporter 2-Mediated Carnitine Uptake in Placental Choriocarcinoma (BeWo) Cells

Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas

Received June 7, 2004; accepted August 17, 2004.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
The placental transport of carnitine is significant because the fetus cannot supply itself with adequate amounts of this nutrient. Carnitine deficiencies in infants can lead to symptoms ranging from muscle weakness to sudden infant death. Objectives of this study include the characterization of novel organic cation transporter 2 (OCTN2) function in the BeWo cell line and the inhibition of placental carnitine uptake by amphetamine derivatives. BeWo cells were seeded in 12- or 24-well tissue culture plates and incubated at 37°C until monolayers were confluent. Uptake studies with radiolabeled L-carnitine and inhibitors in Hanks' balanced salt solution were carried out in the plates at 37°C for 30 min. Uptake of L-carnitine in BeWo cells was Na⁺-dependent and saturable (K_m = 9.8 ± 2.4 µM, V_max = 800 ± 70 pmol/mg of protein/30 min) with a nonsaturable constant of 2.8 ± 0.3 µl/mg of protein/30 min. Among the amphetamine analogs studied, IC₅₀ values ranged from 2.3 to 9.2 mM, and the inhibition of carnitine uptake was stronger for compounds having a methyl-substituted nitrogen atom. Lineweaver-Burk plots show that inhibition by tetraethylammonium and valproate was competitive; inhibition by ephedrine was not completely competitive. The observed kinetics, Western blot, and inhibition profiles indicate that high-affinity carnitine uptake in the BeWo cell line is mediated by OCTN2. Inhibition of carnitine transport by amphetamines potentially poses serious consequences for fetal development.

Organic cation transporters (OCTs) play an important role in the absorption and distribution of many drugs and endogenous compounds. Although it is clear that some OCTs are active in transporting nutrients and other metabolites, the physiological functions of all membrane transporters are not yet known (Ganapathy et al., 2000b). When a drug or xenobiotic compound is recognized by these transporters, not only is cell entry possible for the compound but also the compound can inhibit the transport of physiological substrates. Active transport of organic cations is also significant to pharmaceutical research because many OCT substrates are also substrates for multidrug resistance proteins.

Novel organic cation transporter 2 (OCTN2) is a Na⁺-dependent carnitine transporter expressed in the placenta and other tissues (Lahjouji et al., 2001). L-Carnitine is necessary for the mitochondrial oxidation of fatty acids. Placental transport of carnitine is especially important, because the fetus is not capable of synthesizing sufficient amounts of this nutrient (Wu et al., 1999). Mutations of OCTN2 causing decreased carnitine transport result in primary carnitine deficiency; the impaired fatty acid oxidation brought about by this condition can lead to cardiomyopathy, muscle weakness, hypoketotic hypoglycemia, Reye's syndrome, and sudden infant death (Wang et al., 2000; Lahjouji et al., 2001). Drug-induced inhibition of carnitine transport may also lead to lower plasma carnitine levels and symptoms of carnitine deficiency (Tein et al., 1993).

Several drugs have been shown to induce carnitine deficiencies, including anticonvulsants (e.g., valproic acid) (Tein et al., 1993; Verrotti et al., 1999; Wu et al., 2004), antibiotics (e.g., cephaloridine and emetine) (Ganapathy et al., 2000a; Wagner et al., 2000), and pivalic acid (Okudaira et al., 2001). Although each of these drugs causes depletion of plasma carnitine levels, the mechanisms differ. Cephaloridine and emetine inhibit OCTN2-mediated carnitine uptake (Ganapathy et al., 2000a; Wagner et al., 2000), but administration of pivalic acid leads to the production of pivaloylcarnitine conjugates, the excretion of which results in lower plasma carnitine concentrations (Brass, 2002).

Unfortunately, drug abuse during pregnancy continues to be a significant problem (Huestis and Choo, 2002); some women even use illegal drugs as a means of relieving discomforts experienced in pregnancy. The interference of these drugs with placental nutrient exchange can lead to serious developmental consequences for the baby. Abuse of amphetamines during pregnancy has been linked to low birth weight, premature delivery, brain hemorrhage, infarction, cavitary lesions, and increased risks of neonatal seizures and sudden infant death syndrome (Huestis and Choo, 2002). Amphetamines have been shown to strongly inhibit the serotonin and norepinephrine transporters in the placenta (Ramamoorthy et al., 1995). These illegal drugs have also been linked to decreased mitochondrial function (Burrows et al., 2000), and it has been suggested that carnitine may play a role in attenuating the toxic effects of methamphetamine (Virmani et al., 2003).

Objectives of this study include the characterization of OCTN2 function in the BeWo choriocarcinoma cell line and the inhibition of placental carnitine uptake by amphetamine derivatives. BeWo cells form monolayers in culture and serve as an in vitro model of the rate-limiting barrier for maternal-fetal exchange (Young et al., 2002).

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Cell Culture. The BeWo cell line (clone b30) was obtained from Dr. Alan Schwartz (Washington University, St. Louis, MO). Passages 29 through 40 of the cells were used in this study, cultured as described previously (Young et al., 2002). Briefly, the cells were cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich, St. Louis, MO) adjusted to pH 7.4 and containing 10% heat-inactivated fetal bovine serum (Atlanta Biologicals, Norcross, GA) and 1% each of 200 mM (100x) L-glutamine, 10,000 units/ml penicillin with 10 mg/ml streptomycin, and 10 mM (100x) minimal essential medium nonessential amino acids solution (all three from Invitrogen, Carlsbad, CA). Cells were maintained at 37°C in 150-cm² flasks under 5% CO₂ and 95% relative humidity; the medium was changed every other day. Cells were harvested with trypsin-EDTA solution (Sigma-Aldrich) diluted in phosphate-buffered saline (PBS; 129 mM NaCl, 2.5 mM KCl, 7.4 mM Na₂HPO₄, and 1.3 mM KH₂PO₄, adjusted to pH 7.4).

Western Blotting. Cellular lysate from confluent monolayers of BeWo cells grown in 150-cm² flasks was obtained, and Western blotting was performed as described previously (Hamilton et al., 2001), except that the staining with Ponceau S was omitted. Electrophoresis was carried out in a 12% Tris-glycine gel (Invitrogen) at 110 V for 2 h, and the transfer to a nitrocellulose membrane (Invitrogen) was at 25 V for 2 h on ice. The primary antibody was rabbit anti-mouse OCTN2 affinity pure IgG (Alpha Diagnostic International, San Antonio, TX) at a concentration of 10 µg/ml, and the secondary antibody was peroxidase-conjugated AffiniPure goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories, West Grove, PA), diluted 1:10,000. The enhanced chemiluminescence Western blotting detection reagents were obtained from Amersham Biosciences UK, Ltd. (Little Chalfont, Buckinghamshire, UK).

Uptake Experiments. Before seeding BeWo cells in 12- or 24-well tissue culture plates, the plates (Corning Costar, Corning, NY) were prepared by coating each well in a 12-well plate with 100 µl of a 5 µg/ml poly-D-lysine (Sigma-Aldrich) solution in 28% ethanol (70 µl was added to each well in a 24-well plate). The plates dried under fluorescent light for 3 h in a sterile hood and were then exposed to ultraviolet light for 1 h. At this point, the plates could either be wrapped and refrigerated for up to 2 weeks, or preparation for cell seeding could continue under sterile conditions, with 1 ml of PBS warmed to 37°C added to each well of 12-well plates warmed to room temperature (0.5 ml of PBS was used in 24-well plates). After 30 min, the PBS was aspirated, and 3 drops of a 50 µg/ml fibronectin (Sigma-Aldrich) solution in PBS were added to each well in 12-well plates (2 drops were added in 24-well plates). Once even coating of the fibronectin solution had been verified, the plates were dried for 45 to 90 min under fluorescent light. Immediately before cell seeding, 1 ml of Dulbecco's modified Eagle's medium was added to each well (0.5 ml in 24-well plates) and then aspirated. BeWo cells were seeded in the plates as described previously (Young et al., 2002) but at a density of 12,500 cells/cm². The cells were incubated and medium was changed every other day until 100% confluent (4–6 days).

The uptake experiments in BeWo cells were carried out as described previously (Young et al., 2002). The cells were washed three times with Hanks' balanced salt solution (HBSS, Sigma-Aldrich) and then equilibrated in HBSS at 37°C for approximately 45 min. [³H]L-Carnitine hydrochloride (Moravek Biochemicals, Brea, CA) premixed with (or without) inhibitors in warm HBSS was added to the cells in a shaking hot box (37°C) for 30 min. The dosing solutions were then aspirated, and the cells were washed with ice-cold HBSS three times before the lysing solution (0.5% Triton X-100 in 0.2 N NaOH) was added, and the plate continued to shake in the hot box for approximately three hours. Samples of the lysate were then collected for scintillation spectrometry (LS 60001C, Beckman Coulter, Fullerton, CA) and protein assay using a kit from Pierce Chemical (Rockford, IL) with bovine serum albumin as the standard.

The inhibitor compounds L-carnitine hydrochloride (unlabeled), D-carnitine hydrochloride, acetyl-DL-carnitine hydrochloride, tetraethylammonium (TEA) chloride, 1-methyl-4-phenylpyridinium (MPP⁺) iodide, sodium valproate, choline chloride, (+)-methamphetamine hydrochloride, (+)-ephedrine hydrochloride, (+)--ephedrine hemisulfate salt, and D-amphetamine sulfate were purchased from Sigma-Aldrich. (–)-Norephedrine hydrochloride and (+)-nor--ephedrine hydrochloride were supplied by the National Institute on Drug Abuse (Rockville, MD). Dr. William Soine (Virginia Commonwealth University, Richmond, VA) kindly provided the chloroephedrine hydrochloride compounds.

It was difficult to adjust the pH of HBSS; therefore, pH-dependent uptake studies were carried out in Krebs-Ringer buffer (123 mM NaCl, 4.93 mM KCl, 1.23 mM MgSO₄, 0.85 mM CaCl₂, 5 mM glucose, 5 mM glutamine, 10 mM HEPES, and 10 mM MES) (Said et al., 2002). The pH was adjusted using HCl and KOH because titration with NaOH would result in increased uptake due to the Na⁺-coupled transport of carnitine by OCTN2. The sodium dependence of carnitine uptake was investigated by replacing the NaCl in Krebs-Ringer buffer with 123 mM N-methyl-D-glucamine chloride (Sigma-Aldrich). Sodium gluconate (123 mM) and 4.93 mM potassium gluconate (both from Sigma-Aldrich) replaced NaCl and KCl in Krebs-Ringer buffer to study the chloride dependence of the uptake.

The chloroephedrine compounds are stable for at least 8 h when the pH is between 5 and 6, but at pH 7.4, decomposition may occur within minutes. For these reasons, the uptake experiments involving the chloroephedrines as inhibitors were shortened to 20 min, and these studies (and appropriate controls) were carried out in Krebs-Ringer buffer adjusted to pH 5.2. All other uptake inhibition studies were performed in HBSS for 30 min, which was verified to represent the initial rate.

Data Analysis. The saturable uptake data (picomoles per 30 min per milligram of protein) were fit to the following equation:

(1)

where V, V_max, C, K_m, and k represent the uptake rate, maximum uptake rate, carnitine concentration, the half-saturation concentration (Michaelis constant), and the nonsaturable constant, respectively. Uptake in the presence of inhibitors was calculated as percentage of control (uptake in the absence of any inhibitor). The IC₅₀ values (inhibitor concentration at which inhibition is 50%) were calculated from the following equation:

(2)

where [I] is the inhibitor concentration, min is the minimum uptake (as [I] approaches ), and Hillslope is the slope factor. Regression was performed using SigmaPlot software (SPSS Inc., Chicago, IL). Errors associated with reported values represent the standard deviation calculated from three or four determinations.

To assess the competitive nature of certain inhibitors, Lineweaver-Burk plots were generated. In cases of competitive inhibition, K_i values were determined from the slopes of the plots, according to the following equation:

(3)

However, where the inhibition was not purely competitive, both K_i and K_i' values were obtained from the following equation:

(4)

	Results

Top Abstract Materials and Methods Results Discussion References

 
The Western blot in Fig. 1 demonstrates the expression of OCTN2 in BeWo cells. Bands occurred between 50 and 64 kDa, which is in agreement with the calculated molecular weight of hOCTN2 (62.7 kDa). Similar bands also occurred in the cell lysate of Calu-3 cells (a human submucosal gland cell line) analyzed simultaneously.

View larger version (46K): [in this window] [in a new window]   Fig. 1. Western blot of OCTN2 in BeWo and Calu-3 cells. Lane assignments were: 1) 20 µg of Calu-3 cell lysate; 2) 10 µg of Calu-3 cell lysate; 3) 20 µg of BeWo cell lysate; and 4) 10 µg of BeWo cell lysate. Electrophoresis in 12% Tris-glycine gel for 2 h at 110 V was followed by a 2-h, 25-V transfer to nitrocellulose membrane and overnight blocking. The primary antibody was rabbit anti-mouse OCTN2 IgG; the secondary antibody was goat anti-rabbit IgG. Detection was by enhanced chemiluminescence method.

The uptake of [³H]L-carnitine with varying pH is shown in Fig. 2. The uptake of L-carnitine was independent of pH in the range of 6.5 to 8.0, but below pH 6.5, the uptake decreased as the pH decreased. L-Carnitine uptake in BeWo cells was dependent on the presence of sodium ions, as the uptake decreased significantly (p < 0.001) when the NaCl in the transport buffer was replaced by N-methyl-D-glucamine chloride (Fig. 3). In the presence of Na⁺, administration of 10 nM [³H]L-carnitine resulted in an uptake of 0.582 ± 0.066 pmol/30 min/mg of protein, and in the absence of sodium, this uptake was reduced to 0.385 ± 0.008 pmol/30 min/mg of protein. No significant dependence on chloride ion was observed, however. The replacement of NaCl and KCl with sodium gluconate and potassium gluconate resulted in an uptake that was 107.7 ± 7.2% of control.

View larger version (9K): [in this window] [in a new window]   Fig. 2. pH dependence of [3H]L-carnitine uptake by BeWo cell monolayers. Uptake was measured at 37°C for 30 min in Krebs-Ringer buffer, with pH adjusted using HCl and KOH; each point and error bar represents the average and standard deviation for three to four determinations.

View larger version (15K): [in this window] [in a new window]   Fig. 3. Sodium dependence and chloride dependence of [3H]L-carnitine uptake by BeWo cell monolayers. Uptake was measured at 37°C for 30 min in Krebs-Ringer buffer containing 123 mM NaCl and 4.93 mM KCl (Control); NaCl replaced with 123 mM N-methyl-D-glucamine chloride (–Na+); or NaCl and KCl replaced with 123 mM sodium gluconate and 4.93 mM potassium gluconate (–Cl–). Data are presented as the average and standard deviation for four determinations. ***, p < 0.001.

L-Carnitine uptake in BeWo cells was saturable, as shown in Fig. 4. The K_m value was determined to be 9.8 ± 2.4 µM, with a V_max of 800 ± 70 pmol/30 min/mg of protein. The uptake was linear up to 30 min (data not shown); therefore, all reported values correspond to the initial rate. A nonsaturable constant was also obtained; the value for k from eq. 1 was found to be 2.8 ± 0.3 µl/30 min/mg of protein.

View larger version (15K): [in this window] [in a new window]   Fig. 4. Concentration-dependent uptake of [3H]L-carnitine by BeWo cell monolayers. Uptake was measured at 37°C for 30 min; each point and error bar represents the average and standard deviation for three to four determinations. The fitted line includes both saturable and nonsaturable components, calculated from the obtained kinetic parameters. The dotted line represents the nonsaturable component of the uptake.

The uptake of [³H]L-carnitine was strongly inhibited by unlabeled L-carnitine, its stereoisomer (D-carnitine), and acetyl-DL-carnitine. Figure 5 shows that the inhibition by the organic cations TEA and MPP⁺ and by sodium valproate was not as strong as that of the carnitine analogs. This figure shows two distinct regions of inhibitory efficacy, and Table 1 shows that the IC₅₀ values are in the micromolar range for the carnitines and in the millimolar range for the other compounds. At the highest concentration of choline studied (30 mM), choline only inhibited the carnitine uptake to 57 ± 9% of control. This incomplete inhibition profile precluded the determination of an IC₅₀ value for choline.

View larger version (19K): [in this window] [in a new window]   Fig. 5. Inhibition of [3H]L-carnitine uptake in BeWo cells by various concentrations of L-carnitine, D-carnitine, acetyl-DL-carnitine, TEA, MPP+, sodium valproate, and choline. Inhibitors were premixed with 10 nM [3H]L-carnitine in HBSS. Results of the 30-min experiments at 37°C are presented as percentage of the control situation (10 nM [3H]L-carnitine uptake in the absence of inhibitor). Each point and error bar represent the average and standard deviation for three to four determinations of uptake corrected for protein content. Fitted lines reflect the IC50 values presented in Table 1, obtained as described in the text. As choline did not completely inhibit carnitine uptake, no fitted line was generated.

The amphetamine derivatives studied also inhibited the carnitine uptake in BeWo cells, with IC₅₀ values similar to those of TEA and MPP⁺. Table 2 lists these drugs in order of increasing IC₅₀ values, which range from 2.3 mM (methamphetamine) to 9.2 mM (nor--ephedrine). The structural substituent assignments R₁, R₂, and R₃ in the table correspond to Fig. 6.

View larger version (10K): [in this window] [in a new window]   Fig. 6. Template chemical structure corresponding to the amphetamine derivatives listed in Table 2. Assignments for substituents R1, R2 and R3 are given in Table 2.

Lineweaver-Burk plots in Figs. 7 and 8 show that inhibition of carnitine uptake in BeWo cells is competitive for TEA and valproate, respectively. In the presence of 5.0 mM TEA, the K_m value for carnitine uptake increased from 9.8 ± 2.1 to 50.3 ± 12.6 µM, whereas the V_max did not change significantly (770 ± 180 pmol/30 min/mg of protein in the absence of TEA, and 920 ± 210 pmol/30 min/mg of protein in presence of 5.0 mM TEA). Similarly, 5.0 mM sodium valproate caused the K_m value to increase from 17.8 ± 8.3 to 34.6 ± 12.7 µM and the V_max to go from 490 ± 100 to 560 ± 90 pmol/15 min/mg of protein. The K_i values were determined to be 1.2 ± 0.5 mM for TEA and 2.0 ± 0.7 mM for valproate.

View larger version (19K): [in this window] [in a new window]   Fig. 7. Lineweaver-Burk plot for inhibition of various concentrations of [3H]L-carnitine uptake in BeWo cells by 2.5 and 5.0 mM TEA at 37°C for 30 min. Data for the control situation (no inhibitor) are also presented. Each point and error bar represents the average and standard deviation for three to four determinations of uptake corrected for protein content.

View larger version (19K): [in this window] [in a new window]   Fig. 8. Lineweaver-Burk plot for inhibition of various concentrations of [3H]L-carnitine uptake in BeWo cells by 5.0 mM sodium valproate at 37°C for 15 min. Data for the control situation (no inhibitor) are also presented. Each point and error bar represents the average and standard deviation for three to four determinations of uptake corrected for protein content.

Whereas a similar concentration of ephedrine (4.5 mM) also caused the K_m value to increase from 9.8 ± 2.1 to 15.2 ± 6.9 µM, there was also an accompanying decrease in the V_max value, from 770 ± 180 to 570 ± 360 pmol/30 min/mg of protein (the same control experiment was used for both TEA and ephedrine). The decrease in V_max was more pronounced in the presence of 9.0 mM ephedrine, where the V_max for carnitine uptake in BeWo cells was only 380 ± 50 pmol/30 min/mg of protein. This decrease in V_max, together with the intersection of the lines occurring slightly to the left of the y-axis in Fig. 9, suggests that the inhibition of carnitine uptake in BeWo cells by ephedrine is not completely competitive. For ephedrine, the K_i value was found to be 3.6 ± 0.9 mM, and K_i' was 6.7 ± 3.0 mM, suggesting mixed inhibition.

View larger version (21K): [in this window] [in a new window]   Fig. 9. Lineweaver-Burk plot for inhibition of various concentrations of [3H]L-carnitine uptake in BeWo cells by 1.5, 4.5, and 9.0 mM (+)-ephedrine hydrochloride at 37°C for 30 min. Data for the control situation (no inhibitor) are also presented. Each point and error bar represents the average and standard deviation for three to four determinations of uptake corrected for protein content.

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
In the BeWo choriocarcinoma cell line, OCTN2 mediates the uptake of L-carnitine. This protein is present in BeWo cells, as demonstrated by Western blot, and the observed pH dependence, kinetics, and inhibition profiles are in good agreement with the literature. The pH dependence of carnitine uptake by BeWo cells corresponds well with the results shown by Ohashi et al. (1999) in hOCTN2-transfected HEK293 cells. For the concentration-dependent uptake of carnitine in BeWo cells, we present a K_m value of 9.8 µM, whereas Tamai et al. (1998) report a K_m value of 4.3 µM in OCTN2-transfected HEK293 cells, and a K_m value of 12.6 µM in JAR cells is reported by Ganapathy et al. (2000a).

The observed Na⁺-dependent carnitine uptake with no Cl^– dependence agrees with results observed in JAR cells (Prasad et al., 1996), where the replacement of NaCl with LiCl resulted in a 43% reduction in carnitine uptake. Prasad et al. (1996) saw reductions that are more pronounced when NaCl was replaced with KCl and choline chloride, which could be attributed to the combination of sodium dependence with electrogenic effects and substrate inhibition, respectively.

Our observed nonsaturable component of carnitine uptake may be due to another transporter present in BeWo cells with a lower affinity for carnitine than that of OCTN2. The fact that sodium replacement caused the uptake to decrease by only 34% also suggests significant participation of some non-OCTN2-mediated carnitine transport. However, the sodium replacement experiment does not represent a total sodium-depleted state, but rather a sodium-deficient state, which may account for the lack of a more complete reduction in carnitine uptake. Further experimentation will be required to precisely define the fraction of transport attributable to OCTN2. Considering that other researchers have shown multiple OCT forms that transport carnitine (Tamai et al., 1998; Yabuuchi et al., 1999), our results are consistent with involvement of more than one mechanism being represented in these data.

Ohashi et al. (1999) have observed significant inhibition of carnitine uptake by TEA, MPP⁺, and valproate in hOCTN2-transfected HEK293 cells, as 500 µM of each diminished carnitine uptake to 53.6, 69.8, and 82.3% of control, respectively (Ohashi et al., 1999). Our observed IC₅₀ values of 1.2, 1.7, and 2.6 mM for TEA, MPP⁺, and valproate, respectively, are in good agreement. The stereospecificity of OCTN2-mediated carnitine uptake can be assessed by comparison of the IC₅₀ values of L-carnitine and D-carnitine. In BeWo cells, OCTN2 has a 4-fold higher affinity for L-carnitine than for its enantiomer. The same research group that had shown a K_m of 4.3 µM for L-carnitine uptake in transfected cells observed that D-carnitine is taken up with a K_m value of 10.9 µM (Tamai et al., 1998; Ohashi et al., 1999).

Although it has structural similarity to carnitine, choline is not a potent inhibitor of OCTN2-mediated carnitine uptake. Prasad et al. (1996) observed that although 100 and 500 µM choline resulted in minimal inhibition of carnitine uptake, a very high concentration of choline (40 mM) did inhibit the uptake by 27%. Similarly, our results show that no substantial inhibition of carnitine uptake in BeWo cells was observed at concentrations below 1 mM choline, but 30 mM choline inhibited the uptake by 43%.

The presence of two recognition sites on the carnitine transporter was suggested previously (Bøhmer and Mølstad, 1980), and Ohashi et al. (2002) recently proposed a model of carnitine recognition by OCTN2, with TEA and valproate as the representative substrates for the cationic and anionic binding sites (Ohashi et al., 2002). Consistent with this model, the Lineweaver-Burk plots here show that both TEA and valproate competitively inhibit carnitine uptake in BeWo cells. The K_i values regressed from these plots are in good agreement with the IC₅₀ values obtained from separate experiments.

Several mechanisms have been hypothesized for valproate-induced carnitine deficiency, including elimination of valproyl-carnitine esters, inhibition of mitochondrial fatty acid oxidation upon interactions with enzymes, and impaired carnitine transport (Tein et al., 1993; Raskind and Chaar, 2000). Whereas all of these mechanisms are possible, the competitive inhibition of OCTN2-mediated carnitine uptake by valproate in BeWo cells suggests that the latter mechanism is of significance. Administration of valproic acid during pregnancy may reduce fetal carnitine stores, which will be necessary for the newborn to metabolize the fatty acids present in milk.

Amphetamines strongly inhibit the serotonin and norepinephrine transporters in placenta (Ganapathy et al., 1999), and some inhibition of rOCTN2-mediated TEA uptake by amphetamine and methamphetamine was observed in HRPE cells (Wu et al., 1999). The extent of the interference of these drugs of abuse with the placental carnitine transporter has been examined in this study.

All of the amphetamine derivatives studied inhibited placental carnitine uptake, with IC₅₀ values between 2.3 and 9.2 mM. Among the amphetamine analogs studied, the inhibition is stronger if a methyl group is present on the nitrogen atom (substituent R₃ in Fig. 6). This inhibition pattern suggests that OCTN2 recognizes a substituted nitrogen more readily than an unsubstituted nitrogen at its cationic binding site. Carnitine has three methyl groups on its nitrogen atom.

During the inhibition studies with these drugs, it was interesting to note that at high concentrations, methamphetamine (16 mM), -ephedrine (16 mM), amphetamine (8 mM), and nor--ephedrine (20 mM) were toxic to the BeWo cells, as cell detachment from the experimental plates was observed and as verified by trypan blue exclusion. However, ephedrine and norephedrine, the only compounds having a hydroxyl group in the R₂ position, were not cytotoxic at a concentration of 16 mM.

Although these drugs of abuse inhibit placental carnitine uptake, the affinity of OCTN2 for amphetamines is much lower than that of the serotonin and norepinephrine transporters. K_i values for the inhibition of serotonin uptake by amphetamines are in the micromolar range (Ganapathy et al., 1999). Whereas placental monoamine transporters are primary targets for amphetamines, OCTN2 may be an alternative target for adverse pharmacological effects. Valproic acid uptake in BeWo cells is mediated by a transport system with a K_m value of 200 µM (Utoguchi and Audus, 2000). Nevertheless, valproate competitively inhibits OCTN2 in placenta, and valproate-induced carnitine deficiency is of clinical concern.

This study has shown that high concentrations of amphetamines inhibit OCTN2-mediated carnitine uptake in BeWo cells, an in vitro model of human trophoblasts. Methamphetamine has also been shown to interfere with mitochondrial function, a physiological domain of carnitine (Burrows et al., 2000; Virmani et al., 2003). Although this study does not establish whether amphetamine abuse during pregnancy leads to symptoms of carnitine deficiency, it is of potential concern. This study shows high selectivity and specificity of BeWo OCTN2 for carnitine analogs, and the structure-activity information indicates the preference of OCTN2 for cations with substituted nitrogen atoms.

	Footnotes

 
Financial support for this work has been supplied by the Madison and Lila Self Graduate Fellowship, the University of Kansas Department of Pharmaceutical Chemistry, and Grant HD039878 from the National Institute of Child Health and Human Development. A portion of this work was presented at the AAPS 2003 Annual Meeting, 2003 October 26–30; Salt Lake City, UT. AAPS PharmSci Vol. 5, Abstract T2153 (2003).

doi:10.1124/jpet.104.072363.

ABBREVIATIONS: OCT, organic cation transporter; OCTN2, novel organic cation transporter 2; PBS, phosphate-buffered saline; HBSS, Hanks' balanced salt solution; TEA, tetraethylammonium; MPP⁺, 1-methyl-4-phenylpyridinium; MES, 2-(N-morpholino)ethanesulfonic acid.

Address correspondence to: Dr. Kenneth L. Audus, School of Pharmacy, University of Kansas, 1251 Wescoe Hall Dr., Lawrence, KS 66045. E-mail: audus{at}ku.edu

	References

Top Abstract Materials and Methods Results Discussion References

 

Bøhmer T and Mølstad P (1980) Carnitine transport across the plasma membrane, in Carnitine Biosynthesis, Metabolism and Functions (Frenkel RA and McGarry JD eds) pp 73–89, Academic Press, New York.

Brass EP (2002) Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol Rev 54: 589–598.[Abstract/Free Full Text]

Burrows KB, Gudelsky G, and Yamamoto BK (2000) Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration. Eur J Pharmacol 398: 11–18.[CrossRef][Medline]

Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, and Ganapathy V (2000a) beta-Lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem 275: 1699–1707.[Abstract/Free Full Text]

Ganapathy V, Prasad PD, Ganapathy ME, and Leibach FH (1999) Drugs of abuse and placental transport. Adv Drug Deliv Rev 38: 99–110.[CrossRef][Medline]

Ganapathy V, Prasad PD, Ganapathy ME, and Leibach FH (2000b) Placental transporters relevant to drug distribution across the maternal-fetal interface. J Pharmacol Exp Ther 294: 413–420.[Free Full Text]

Hamilton KO, Backstrom G, Yazdanian MA, and Audus KL (2001) P-glycoprotein efflux pump expression and activity in Calu-3 cells. J Pharm Sci 90: 647–658.[CrossRef][Medline]

Huestis MA and Choo RE (2002) Drug abuse's smallest victims: in utero drug exposure. Forensic Sci Int 128: 20–30.[CrossRef][Medline]

Lahjouji K, Mitchell GA, and Qureshi IA (2001) Carnitine transport by organic cation transporters and systemic carnitine deficiency. Mol Genet Metab 73: 287–297.[CrossRef][Medline]

Ohashi R, Tamai I, Inano A, Katsura M, Sai Y, Nezu JI, and Tsuji A (2002) Studies on functional sites of organic cation/carnitine transporter OCTN2 (SLC22A5) using a Ser467Cys mutant protein. J Pharmacol Exp Ther 302: 1286–1294.[Abstract/Free Full Text]

Ohashi R, Tamai I, Yabuuchi H, Nezu J, Oku A, Sai Y, Shimane M, and Tsuji A (1999) Na+-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther 291: 778–784.[Abstract/Free Full Text]

Okudaira N, Fujigaki M, Nakayoshi T, Komiya I, and Sugiyama Y (2001) Upregulation of carnitine transporters helps maintain tissue carnitine levels in carnitine deficiency induced by pivalic acid. Pharm Res (NY) 18: 439–445.

Prasad PD, Huang W, Ramamoorthy S, Carter AL, Leibach FH, and Ganapathy V (1996) Sodium-dependent carnitine transport in human placental choriocarcinoma cells. Biochim Biophys Acta 1284: 109–117.[Medline]

Ramamoorthy JD, Ramamoorthy S, Leibach FH, and Ganapathy V (1995) Human placental monoamine transporters as targets for amphetamines. Am J Obstet Gynecol 173: 1782–1787.[CrossRef][Medline]

Raskind JY and El Chaar GM (2000) The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 34: 630–638.[Abstract]

Said HM, Ortiz A, and Vaziri ND (2002) Mechanism and regulation of vitamin B-6 uptake by renal tubular epithelia: studies with cultured OK cells. Am J Physiol 282: F465–F471.

Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, Sai Y, and Tsuji A (1998) Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 273: 20378–20382.[Abstract/Free Full Text]

Tein I, Dimauro S, Xie ZW, and Devivo DC (1993) Valproic acid impairs carnitine uptake in cultured human skin fibroblasts - an in-vitro model for the pathogenesis of valproic acid associated carnitine deficiency. Pediatr Res 34: 281–287.[Medline]

Unadkat JD, Dahlin A, and Vijay S (2004) Placental drug transporters. Curr Drug Metab 5: 125–131.[CrossRef][Medline]

Utoguchi N and Audus KL (2000) Carrier-mediated transport of valproic acid in BeWo cells, a human trophoblast cell line. Int J Pharm 195: 115–124.[CrossRef][Medline]

Verrotti A, Greco R, Morgese G, and Chiarelli F (1999) Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs. Int J Clin Lab Res 29: 36–40.[CrossRef][Medline]

Virmani A, Gaetani F, Imam S, Binienda Z, and Ali S (2003) Possible mechanism for the neuroprotective effects of L-carnitine on methamphetamine-evoked neurotoxicity. Ann NY Acad Sci 993: 197–207.[Medline]

Wagner CA, Lukewille U, Kaltenbach S, Moschen I, Broer A, Risler T, Broer S, and Lang F (2000) Functional and pharmacological characterization of human Na+-carnitine cotransporter hOCTN2. Am J Physiol 279: F584–F591.

Wang YH, Meadows TA, and Longo N (2000) Abnormal sodium stimulation of carnitine transport in primary carnitine deficiency. J Biol Chem 275: 20782–20786.[Abstract/Free Full Text]

Wu SP, Shyu MK, Liou HH, Gau CS, and Lin CJ (2004) Interaction between anticonvulsants and human placental carnitine transporter. Epilepsia 45: 204–210.[CrossRef][Medline]

Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen JW, Conway SJ, and Ganapathy V (1999) Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther 290: 1482–1492.[Abstract/Free Full Text]

Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, and Tsuji A (1999) Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther 289: 768–773.[Abstract/Free Full Text]

Young A, Fukuhara A, and Audus KL (2002) BeWo cells: an in vitro system representing the blood-placental barrier, in Cell Culture Models of Biological Barriers: In-Vitro Test Systems for Drug Absorption and Delivery (Lehr C-M ed) pp 337–349, Taylor & Francis, London.

This article has been cited by other articles:

				G. D'Argenio, M. Calvani, A. Casamassimi, O. Petillo, S. Margarucci, M. Rienzo, I. Peluso, R. Calvani, A. Ciccodicola, N. Caporaso, et al. Experimental colitis: decreased Octn2 and Atb0+ expression in rat colonocytes induces carnitine depletion that is reversible by carnitine-loaded liposomes FASEB J, December 1, 2006; 20(14): 2544 - 2546. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.104.072363v1 312/1/192    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rytting, E. Articles by Audus, K. L. Search for Related Content PubMed PubMed Citation Articles by Rytting, E. Articles by Audus, K. L.